[1] Ferlay J, Shin H R, Bray F, Forman D, Mathers C, Parkin D M. Int. J. Cancer., 2010, 127: 2893—2917
[2] Cancer Research U K. Cancer Stats.Breast Cancer 2011.[2013-03-18]. http://www.cancerresearchuk.org/cancer-info/cancerstats/world/breast-cancer-world/#Mortality
[3] Siegel R, Naishadham D, Jemal A. CA Cancer J. Clin., 2013, 63:11—30
[4] Nelson H D, Huffman L H, Fu R, Harris E L. Ann. Intern. Med., 2005, 143: 362—379
[5] Kurian A W, Gong G D, Chun N M, Mills M A, Staton A D, Kingham K E, Crawford B B, Lee R, Chan S, Donlon S S, Ridge Y, Panabaker K, West D W, Whittemore A S, Ford J M. J. Clin. Oncol., 2008, 26: 4752—4758
[6] Howell A, Astley S, Warwick J, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Harvie M, Wilson M, Beetles U, Warren R, Hufton A, Sergeant J, Newman W, Buchan I, Cuzick J, Evans D G. J. Intern. Med., 2012, 271: 321—330
[7] Boughey J C, Hartmann L C, Anderson S S, Degnim A C, Vierkant R A, Reynolds C A, Frost M H, Pankratz V S. J. Clin. Oncol., 2010, 28: 3591—3596
[8] Baker L H. CA Cancer J. Clin., 1982, 32: 194—225
[9] Gail M H, Brinton L A, Byar D P, Corle D K, Green S B, Schairer C, Mulvihill J J. J. Natl. Cancer Inst., 1989, 81: 1879—1886
[10] Costantino J P, Gail M H, Pee D, Anderson S, Redmond C K, Benichou J, Wieand H S. J. Natl. Cancer Inst., 1999, 91: 1541—1548
[11] NCI Breast Cancer Risk Assessment Tool. 2011, (2012-05-16).[2013-03-19]. http://www.cancer.gov/bcrisktool/
[12] Gail M H. J. Natl. Cancer Inst., 2008, 100: 1037—1041
[13] Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson H S, Diver W R, Thun M J, Cox D G, Hankinson S E, Kraft P, Rosner B, Berg C D, Brinton L A, Lissowska J, Sherman M E, Chlebowski R, Kooperberg C, Jackson R D, Buckman D W, Hui P, Pfeiffer R, Jacobs K B, Thomas G D, Hoover R N, Gail M H, Chanock S J, Hunter D J. N. Engl. J. Med., 2010, 362: 986—993
[14] Arun B, Dunn B K, Ford L G, Ryan A. Semin. Oncol., 2010, 37: 367—383
[15] Jordan V C, Ed. Tamoxifen. A Guide for Clinicians and Patients. Huntington, NY: PRR, Inc., 1996
[16] Nayfield S G, Karp J E, Ford L G, Dorr F A, Kramer B S. J. Natl. Cancer Inst., 1991, 83: 1450—1459
[17] Early Breast Cancer Trialists' Collaborative Group. Lancet, 1998, 351: 1451—1467.
[18] Early Breast Cancer Trialists' Collaborative Group. Lancet, 2005, 365: 1687—1717
[19] Fisher B, Costantino J, Redmond C, et al. N. Engl. J. Med., 1989, 320: 479—484
[20] Fisher B, Costantino J P, Wickerham D L, et al. J. Natl. Cancer Inst., 1998, 90: 1371—1388
[21] Fisher B, Costantino J P, Wickerham D L, et al. J. Natl. Cancer Inst., 2005, 97: 1652—1662
[22] Powles T, Eeles R, Ashley S, et al. Lancet, 1998, 352: 98—101
[23] Powles T J, Ashley S, Tidy A, Smith I E, Dowsett M. J. Natl. Cancer Inst., 2007, 99: 283—290
[24] Veronesi U, Maisonneuve P, Costa A, et al. Lancet, 1998, 352: 93—97
[25] Veronesi U, Maisonneuve P, Rotmensz N, et al. J. Natl. Cancer Inst., 2003, 95: 160—165
[26] Cuzick J, Forbes J, Edwards R, et al. Lancet, 2002, 360: 817—824
[27] Cuzick J. Eur. J. Cancer, 1998, 34: 1647—1648
[28] Cuzick J, Forbes J F, Sestak I, et al. J. Natl. Cancer Inst., 2007, 99: 272—282
[29] Cuzick J, Powles T, Veronesi U, et al. Lancet, 2003, 361: 296—300
[30] Ettinger B, Black D M, Mitlak B H, et al. JAMA, 1999, 282: 637—645
[31] Cummings S R, Eckert S, Krueger K A, et al. JAMA, 1999, 281: 2189—2197
[32] Vogel V G, Costantino J P, Wickerham D L, et al. JAMA, 2006, 295: 2727—2741
[33] Vogel V G, Costantino J P, Wickerham D L, et al. Cancer Prev. Res. (Phila), 2010, 3: 696—706
[34] Cuzick J. Cancer Prev. Res. (Phila), 2010, 3: 689—691
[35] Cummings S R, Ensrud K, Delmas P D, LaCroix A Z, Vukicevic S, Reid D M, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong R A, Thompson D D, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R. PEARL Study Investigators. N. Engl. J. Med., 2010, 362: 686—696
[36] LaCroix A Z, Powles T, Osborne C K, Wolter K, Thompson J R, Thompson D D, Allred D C, Armstrong R, Cummings S R, Eastell R, Ensrud K E, Goss P, Lee A,Neven P, Reid D M, Curto M, Vukicevic S. PEARL Investigators. J. Natl. Cancer Inst., 2010, 102: 1706—1715
[37] Cummings S R, McClung M, Reginster J Y, Cox D, Mitlak B, Stock J, Amewou-Atisso M, Powles T, Miller P, Zanchetta J, Christiansen C. J. Bone Miner. Res., 2011, 26: 397—404
[38] Coombes R C, Hall E, Gibson L J, Paridaens R, Jassem J, Delozier T, Jones S E, Alvarez I, Bertelli G, Ortmann O, Coates A S, Bajetta E, Dodwell D, Coleman R E, Fallowfield L J, Mickiewicz E, Andersen J, Lønning P E, Cocconi G, Stewart A, Stuart N, Snowdon C F, Carpentieri M, Massimini G, Bliss J M, vande Velde C. Intergroup Exemestane Study. N. Engl. J. Med., 2004, 350: 1081—1092
[39] Coombes RC, Kilburn LS, Snowdon CF, et al. Lancet, 2007, 369:559—570
[40] Richardson H, Johnston D, Pater J, Goss P. Curr. Oncol., 2007, 14: 89—96
[41] Khuder S A, Mutgi A B. Br. J. Cancer, 2001, 84: 1188—1192
[42] Hwang D, Scollard D, Byrne J, Levine E. J. Natl. Cancer Inst., 1998, 90: 455—460
[43] Bresalier R S, Sandler R S, Quan H, et al. N. Engl. J. Med., 2005, 352: 1092—1102
[44] Solomon S D, McMurray J J, Pfeffer M A, et al. N. Engl. J. Med., 2005, 352: 1071—1080
[45] Goss P E, Ingle J N, Ales-Martinez J E, et al. N. Engl. J. Med., 2011, 364: 2381—2391
[46] Decensi A, Dunn B K, Puntoni M, Gennari A, Ford L G. Cancer Discovery, 2012, 2: 25—40
[47] Baum M, Budzar A U, Cuzick J, Forbes J, Houghton J H, Klijn J G, Sahmoud T. ATAC Trialists' Group. Lancet, 2002, 359: 2131—2139
[48] Baum M, Buzdar A, Cuzick J, et al. Cancer, 2003, 98: 1802—1810
[49] Howell A, Cuzick J, Baum M, et al. Lancet, 2005, 365: 60—62
[50] Forbes J F, Cuzick J, Buzdar A, Howell A, Tobias J S, Baum M. Lancet Oncol., 2008, 9: 45—53
[51] Cuzick J, Sestak I, Baum M, et al. Lancet Oncol., 2010, 11: 1135—1141
[52] Sestak I, Cuzick J, Sapunar F, et al. Lancet Oncol., 2008, 9: 866—872
[53] Cuzick J. Recent Results Cancer Res., 2003, 163: 96—103; discussion 264—266
[54] Cuzick J. J. Clin. Oncol., 2005, 23: 1636—1643
[55] Cuzick J. Expert Rev. Anticancer Ther., 2008, 8: 1377—1385
[56] International Breast Cancer Intervention Study II. 2012,[2013-03-21]. http://www.ibis-trials.org/
[57] International Breast Cancer Intervention Study-II. Accrual numbers., 2012. [2013-04-03]. http://www.ibis-trials.org/news/viewStory.php?storyId=186
[58] Davies C, Pan H, Godwin J, et al. Lancet, 2013, 381(9869): 805—816
[59] Lazzeroni M, Serrano D, Dunn BK, et al. Breast Cancer Res., 2012,14:214
[60] Heckman-Stoddard B M, Lee O, Lazzeroni M, Khan S, DeCensi A, Dunn B K. Innovative Approaches to Tamoxifen Administration for Breast Cancer Prevention. In: Tamoxifen Concepts and Cancer: New Paradigms: Nova ScienceHauppauge. (Mello RAd, Ed.), NY: Publishers, 2013. in press.
[61] Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al. J. Natl. Cancer Inst., 1998, 90: 1461—1467
[62] Decensi A, Gandini S, Guerrieri-Gonzaga A, et al. J. Clin. Oncol., 1999, 17: 2633—2638
[63] Decensi A, Robertson C, Viale G, et al. J. Natl. Cancer Inst., 2003, 95: 779—790
[64] Kisanga E R, Gjerde J, Guerrieri-Gonzaga A, et al. Clin. Cancer Res., 2004, 10: 2336—2343
[65] Decensi A, Robertson C, Guerrieri-Gonzaga A, et al. J. Clin. Oncol., 2009, 27: 3749—3756
[66] Waters E A, Cronin K A, Graubard B I, Han P K, Freedman A N. Cancer Epidemiol Biomarkers Prev., 2010, 19: 443—446
[67] Tchou J, Hou N, Rademaker A, Jordan V C, Morrow M. Cancer, 2004, 100: 1800—1806
[68] Decensi A, Puntoni M, Goodwin P, et al. Cancer Prev. Res. (Phila), 2010, 3: 1451—1461
[69] Bonanni B, Puntoni M, Cazzaniga M, et al. J. Clin. Oncol., 2012, 30(21): 2593—2600
[70] Szabo E. Semin. Oncol., 2010, 37: 359—366
[71] Goss P E, Ingle J N, Martino S, et al. N. Engl. J. Med., 2003, 349: 1793—1802
[72] Thurlimann B, Keshaviah A, Coates AS, et al. N. Engl. J. Med., 2005, 353: 2747—2757
[73] Coates A S, Keshaviah A, Thurlimann B, et al. J. Clin. Oncol., 2007, 25: 486—492
[74] Regan M M, Neven P, Giobbie-Hurder A, et al. Lancet Oncol., 2011, 12: 1101—1108
[75] Veronesi U, Maisonneuve P, Rotmensz N, et al. J. Natl. Cancer Inst., 2007, 99: 727—737otmensz N, et al. J. Natl. Cancer Inst., 2007, 99:727-737 |